Jakub Svoboda, MD, reports on recent studies in classical Hodgkin lymphoma therapy, including a summation of the phase 3 ECHELON-1 trial, a global comparative (A+AVD vs. ABVD) immunotherapy trial that took place, in part, at the Abramson Cancer Center; a discussion of combination frontline treatments for Hodgkin; and PD1 inhibition for relapsed/refractory patients. Considering ongoing studies at Penn Medicine, Dr. Svoboda also examines the rationale for nonviral RNA CART19 therapy for the T-cell lymphomas.
Related Links:
Enrolling Clinical Trials: Adoptive Immunotherapy for Chemotherapy Resistant or Refractory CD-19+ Leukemia and Lymphoma
Penn Medicine’s Comprehensive Center for Hodgkin Lymphoma
Connect with Dr. Svoboda on Doximity
Dr Svoboda’s Penn Profile
Published
March 8, 2018
Created by
BROADCASTMED